With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead.

Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP & International Managing Director at Alloga Europe and ICS, which are part of Cencora – and the conversation dives into takeaways such as the increase in smaller biotech companies taking their product to market on their own, what is needed to ensure a successful go-to-market strategy, the unique logistics and supply chain considerations specialty pharmaceutical products introduce, and also geographical considerations, with 34 of the 50 novel drugs approved in 2024 being in the US before any other country.

You can listen to episode 178a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!